I'm the author of Airpocalypse, a medical thriller


Welcome to the digital era of biology (and to this modest blog I started in early 2005).

To cure many diseases, like cancer or cystic fibrosis, we will need to target genes (mutations, for ex.), not organs! I am convinced that the future of replacement medicine (organ transplant) is genomics (the science of the human genome). In 10 years we will be replacing (modifying) genes; not organs!


Anticipating the $100 genome era and the P4™ medicine revolution. P4 Medicine (Predictive, Personalized, Preventive, & Participatory): Catalyzing a Revolution from Reactive to Proactive Medicine.


I am an early adopter of scientific MOOCs. I've earned myself four MIT digital diplomas: 7.00x, 7.28x1, 7.28.x2 and 7QBWx. Instructor of 7.00x: Eric Lander PhD.

Upcoming books: Airpocalypse, a medical thriller (action taking place in Beijing) 2017; Jesus CRISPR Superstar, a sci-fi -- French title: La Passion du CRISPR (2018).

I love Genomics. Would you rather donate your data, or... your vital organs? Imagine all the people sharing their data...

Audio files on this blog are Windows files ; if you have a Mac, you might want to use VLC (http://www.videolan.org) to read them.

Concernant les fichiers son ou audio (audio files) sur ce blog : ce sont des fichiers Windows ; pour les lire sur Mac, il faut les ouvrir avec VLC (http://www.videolan.org).


Robotic surgery: a (much) cheaper da Vinci TM

IBIS pneumatic keyhole surgery robot potentially 1/10 the cost of da Vinci TM!

This is a robot system for keyhole surgery, consisting of a master unit operated by the surgeon, and a slave unit that moves on the patient side. (read here).



Un groupe de chercheurs japonais vient de mettre au point un prototype de robot chirurgien baptisé IBIS qui va directement concurrencer le produit phare des robots de santé, le robot Da Vinci d’Intuitive Surgical. Les japonais ont annoncé que leur système coûterait entre trois et dix fois moins que celui des américains. Lire la suite.

Aucun commentaire: